Pfizer Inc. (PFE)[Tv]

Key Developments

• Pfizer Q2 2026 earnings report beat expectations with $15.03B in revenue and $0.77 in adjusted EPS, marking the ninth consecutive quarter of revenue upside and a clear validation of its post-pandemic diversification strategy, despite an earnings dip due to a $4.3B non-cash impairment charge.
• Arbutus Biopharma files international patent lawsuits against Pfizer and BioNTech over alleged infringement of LNP technology—the foundational platform behind the Pfizer-BioNTech COVID-19 vaccine—posing a systemic threat to Pfizer’s mRNA platform, licensing deals, and long-term innovation capacity.
• FDA grants Priority Review for TALZENNA + XTANDI combination therapy in men with HRR-altered mCSPC, a pivotal regulatory milestone that could expand Pfizer’s oncology footprint into earlier-stage prostate cancer and unlock a high-value commercial opportunity.
• Newly upgraded full-year 2026 revenue guidance reflects confidence in Pfizer’s diversified portfolio, with projections now at $60.5B–$62.5B after a $500M upward revision, driven by strong non-COVID product performance and pipeline momentum.
• Berobenatide shows 12.3% weight loss in Phase II-B, positioning Pfizer as a credible contender in the high-stakes GLP-1 obesity market, potentially disrupting the dominance of Eli Lilly and Novo Nordisk and signaling a major step toward capturing the decade’s most lucrative therapeutic trend.

Critical News